New trials, publications, preprints and grants on this target, month by month.
Trial
Aspirin and PAClitaxel in Head & Neck Squamous Cell Carcinoma
31 Dec 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.
15 Dec 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
A Study to Learn About the Study Medicine Called PF-08165784 in People With PIK3CA-Mutated Advanced or Metastatic Solid Tumors
9 Nov 2026· PHASE1 · NOT_YET_RECRUITING· CTGOV
Trial
A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes
30 Oct 2026· PHASE2 · RECRUITING· CTGOV
Publication
PIK3CA Mutations in Advanced or Recurrent Endometrial Cancer: An Exploratory Molecular Profiling From the Phase II MITO END-3 Study.
16 Oct 2026· JCO precision oncology· PUBMED
Trial
JYP0035 Capsules Plus Fulvestrant in PIK3CA-Mutant HR+/HER2- Advanced Breast Cancer
30 Sept 2026· PHASE3 · NOT_YET_RECRUITING· CTGOV
Publication
Efficacy and safety of immune checkpoint inhibitors combined with TKIs for recurrent or metastatic cervical cancer with PIK3CA mutation.
29 Sept 2026· PloS one· PUBMED
Publication
Exceptional response to alpelisib in a heavily pretreated patient with metastatic breast cancer carrying a PIK3CA mutation outside SOLAR-1 eligible mutations: a case report.
23 Sept 2026· Acta oncologica (Stockholm, Sweden)· PUBMED
Publication
Downregulation of miR203 Induces Overexpression of PIK3CA and Predicts Poor Prognosis of Gastric Cancer Patients [Retraction].
18 Sept 2026· Drug design, development and therapy· PUBMED
Publication
Integrated Genomic Profiling of PTEN and TP53 in Cervical Neuroendocrine Carcinoma: Synergistic Roles With HER2/KRAS/PIK3CA and Implications for Precision Oncology.
1 Sept 2026· Genes, chromosomes & cancer· PUBMED
Publication
Correction: Hypoxia and aspirin additively increase intracellular glutamine accumulation in PIK3CA-mutated colorectal cancer cells.
31 Aug 2026· Scientific reports· PUBMED
Publication
Retraction of: APOA5 alleviates reactive oxygen species to promote oxaliplatin resistance in PIK3CA-mutated colorectal cancer.
23 Aug 2026· Aging· PUBMED
Publication
PIK3CA in the transformation of EGFR ‑mutant lung adenocarcinoma to small cell lung cancer following acquired targeted therapy resistance.
21 Aug 2026· Chinese medical journal· PUBMED
Trial
Postoperative Circulating Tumor DNA Monitoring in Stage I-III Driver-Mutant Colon Adenocarcinoma
14 Aug 2026· NA · RECRUITING· CTGOV
Publication
Somatic alterations in TP53, PIK3CA, and CCND1 reveal exposure-driven patterns in oral and oropharyngeal tumors.
13 Aug 2026· Journal of the National Cancer Institute· PUBMED
Publication
Inavolisib for PIK3CA-mutated advanced endometrial cancer: a multicentric, phase II, MITO END-4 trial.
9 Aug 2026· International journal of gynecological cancer : official journal of the International Gynecological Cancer Society· PUBMED
Publication
Prevalence and clinical impact of PIK3CA and PTEN alterations from reflex genomic testing of newly diagnosed colorectal cancer: a population-based series.
7 Aug 2026· Frontiers in oncology· PUBMED
Publication
Recurrent PIK3CA-E545K mutation promotes cervical cancer growth and invasion via AKT/mTOR signaling.
7 Aug 2026· Molecular genetics and genomics : MGG· PUBMED
Publication
Case Report: Concomitant BRAF V600E and PIK3CA H1047R mutations in a micro-papillary thyroid carcinoma with extensive nodal metastasis.
4 Aug 2026· Frontiers in oncology· PUBMED
Publication
Angiogenic switching in cerebral cavernous malformations driven by MAP3K3-PIK3CA synergy.
3 Aug 2026· Brain : a journal of neurology· PUBMED
Publication
Cost-effectiveness of inavolisib-based therapy in PIK3CA-mutated advanced breast cancer in the USA.
27 Jul 2026· Breast (Edinburgh, Scotland)· PUBMED
Publication
DHODH is a synthetic lethal target in PIK3CA-mutant colorectal cancer.
24 Jul 2026· Cell reports· PUBMED
Trial
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
23 Jul 2026· PHASE1 · RECRUITING· CTGOV
Publication
Performance Evaluation of a Colorectal Cancer-Associated MassARRAY-Based Hotspot Genotyping Assay for KRAS, NRAS, BRAF, and PIK3CA Using Solid Tumor Specimens.
23 Jul 2026· Frontiers in bioscience (Landmark edition)· PUBMED
Publication
Correction: Multi-gene co-mutations of BRAF with TERT, PIK3CA, or TP53 are powerful predictors of central lymph node metastasis in papillary thyroid carcinoma.
22 Jul 2026· Frontiers in endocrinology· PUBMED
Trial
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
21 Jul 2026· PHASE1 · RECRUITING· CTGOV
Publication
Adjuvant aspirin for colorectal cancer with PIK3CA-mutated and COX-2 overexpressed tumours: the ASCOLT translational research study and meta-analysis.
20 Jul 2026· EBioMedicine· PUBMED
Publication
Growth of PIK3CA-driven cerebral cavernous malformations does not require microbiome stimulation.
16 Jul 2026· JCI insight· PUBMED
Publication
Oncogenic PIK3CA reprograms glutamine metabolism to drive bladder cancer progression.
14 Jul 2026· Cell communication and signaling : CCS· PUBMED
Publication
PIK3CA mutations and PI3K isoform expression define prognostic signatures in ovarian clear cell carcinoma.
14 Jul 2026· Archives of gynecology and obstetrics· PUBMED